Dietary daidzein and puerarin do not affect pituitary LH expression but exert uterotropic effects in ovariectomized rats.
OBJECTIVE
To investigate the potency of LH suppression, as an indirect measure of alleviation of postmenopausal vasomotor symptoms, as well as the uterotropic effects of two isoflavones: daidzein and puerarin in an ovariectomized (ovx) rat model and compare them with the effects of 17beta-estradiol benzoate (E2B).


METHODS
Eighty female Sprague-Dawley rats were ovx and divided into six different treatment groups and one control group (11-12 animals per group). Daidzein, puerarin and E2B were added to the soy free rodent chow in low and high doses (250 mg and 1000 mg per kg, 600 mg and 3000 mg per kg and 4.3 mg and 17.3 mg per kg, respectively). After 3 months of treatment, animals were sacrificed and using real time RT-PCR, pituitary LHbeta and uterine IGF-1, PR and C3 mRNA levels were measured. Additionally serum LH levels were measured in a radioimmunoassay.


RESULTS
Both of our tested isoflavones at low and high doses had no effect on the expression of the pituitary LH at the mRNA and protein level. Only E2B at both doses significantly decreased pituitary LHbeta gene expression and serum LH levels. Daidzein and puerarin at high dose increased significantly uterine weights. Uterine IGF-1 gene expression was only upregulated in puerarin high group. Uterine PR mRNA levels were higher in animals fed with low dose daidzein and high dose puerarin. Uterine C3 gene expression was upregulated in animals fed with daidzein and puerarin at high doses. Although statistically significant, all these effects were however very discrete compared to those of E2B at low and high doses.


CONCLUSIONS
We speculate that due to the lack of LH suppressing effects in our model, it is very unlikely for daidzein and puerarin to alleviate vasomotor symptoms in postmenopausal women. In contrast, due to their uterotropic effects, high dose consumption of commercially available preparations containing daidzein or puerarin may expose women with an intact uterus to the risk of endometrial hyperplasia.
Rachoń
Dominik
D
Department of Clinical and Experimental Endocrinology, University of Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany. drachon@amg.gda.pl
Vortherms
Tina
T
Seidlova-Wuttke
Dana
D
Wuttke
Wolfgang
W
D000818:Animals; D019587:Dietary Supplements; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology; D004968:Estrogens, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005786:Gene Expression Regulation; D007529:Isoflavones / Q000008:administration & dosage / Q000494:pharmacology*; D007986:Luteinizing Hormone / Q000097:blood / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D010052:Ovariectomy; D010902:Pituitary Gland / Q000378:metabolism; D012333:RNA, Messenger; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014599:Uterus / Q000378:metabolism
D004968:Estrogens, Non-Steroidal; D007529:Isoflavones; D012333:RNA, Messenger; D004958:Estradiol; C004742:daidzein; D007986:Luteinizing Hormone; C033607:puerarin